<DOC>
	<DOC>NCT02639910</DOC>
	<brief_summary>This is a single arm, multicenter, open-label study of MOR00208 combined with idelalisib in adult patients with R/R CLL or R/R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as part of combination therapy.</brief_summary>
	<brief_title>Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)</brief_title>
	<detailed_description>The purpose of this study is to evaluate the clinical safety and efficacy of MOR00208 combined with idelalisib. The study will include a safety run-in phase with an evaluation of the safety data. This evaluation will be done by an Independent Data Monitoring Committee.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Major inclusion criteria Diagnosis/Trial Population Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): history of diagnosis of CLL or SLL that meets IWCLL diagnostic criteria histologically confirmed diagnosis of SLL by lymph node biopsy indication for treatment as defined by the IWCLL guidelines Patients must have both of the following: relapsed or refractory disease while receiving a BTKi therapy or intolerance of such therapy singleagent or combination therapy with a BTKi for at least one month must be the patient's most recent prior anticancer therapy ECOG performance status of 0 to 2 Patients with a past medical history of autologous or allogeneic stem cell transplantation must exhibit full hematological recovery Laboratory Values Patients must meet adequate bone marrow function and adequate hepatic and renal function Other Inclusion Criteria â€¢ Females of childbearing potential must use a highly effective method of contraception Major exclusion criteria Diagnosis Patients who have: nonHodgkin's lymphomas other than CLL/SLL transformed CLL/SLL or Richter's syndrome active and uncontrolled autoimmune cytopenia Previous and Current Treatment Patients who have, within 14 days prior to D1 dosing: not discontinued CD20targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma specific therapy systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day received live vaccines with the exception of vaccination against influenza with inactivated virus or for pneumococcal diseases Patients who: have not recovered sufficiently from the adverse toxic effects of prior therapies were previously treated with CD19targeted therapy or a PI3K inhibitor have a history of previous severe allergic reactions to prior monoclonal antibody therapy, and/or the excipients contained in the study drug formulations Patients with ongoing inflammatory bowel disease as ulcerative colitis, Crohn's disease, chronic diarrhoea, severe chronic obstructive pulmonary disease, pulmonary emphysema or druginduced pneumonitis diagnosed in previous medical history.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CD19</keyword>
	<keyword>MOR208</keyword>
	<keyword>MOR00208</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>COSMOS</keyword>
</DOC>